Watchlist Price Alert

Insmed (INSM)

NASDAQ: INSM · Real-Time Price · USD

67.55

1.39 (2.10%)

At close: May 23, 2025, 3:59 PM

67.75

0.30%

After-hours: May 23, 2025, 04:55 PM EDT

2.10% (1D)

Bid	66.85
Market Cap	12.3B
Revenue (ttm)	381.03M
Net Income (ttm)	-1.01B
EPS (ttm)	-5.93
PE Ratio (ttm)	-11.39
Forward PE	-18.09
Analyst	Buy

Ask	69
Volume	1,283,079
Avg. Volume (20D)	2,230,003
Open	66.04
Previous Close	66.16
Day's Range	65.56 - 67.65
52-Week Range	21.92 - 84.91
Beta	0.84

About INSM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol INSM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for INSM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

-3.88%

Insmed shares are trading lower after the company ... Unlock content with Pro Subscription

9 months ago

+1.16%

Insmed shares are trading lower after the company reported mixed Q2 financial results.

News

1 week ago · zacks.com

Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects

Examine the evolution of Insmed's (INSM) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

2 weeks ago · zacks.com

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.

2 weeks ago · seekingalpha.com

Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript

Insmed Incorporated (NASDAQ:INSM ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Bryan Dunn - Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bons...

2 weeks ago · zacks.com

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago.

3 weeks ago · zacks.com

Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · seekingalpha.com

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

4 weeks ago · seekingalpha.com

Insmed: Poised For Transformation Beyond ARIKAYCE

Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 resul...